Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function

Marie T Borin,1 Arthur Lo,2 Chris N Barnes,3 Srikanth Pendyala,4 David L Bourdet2 1Department of Clinical and Translational Pharmacology, Theravance Biopharma US, Inc., South San Francisco, CA, USA; 2Department of Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francis...

Full description

Bibliographic Details
Main Authors: Borin MT, Lo A, Barnes CN, Pendyala S, Bourdet DL
Format: Article
Language:English
Published: Dove Medical Press 2019-10-01
Series:International Journal of COPD
Subjects:
Liver disease
kidney disease
chronic obstructive pulmonary disease
long-acting muscarinic antagonist
LAMA
revefenacin
Online Access:https://www.dovepress.com/pharmacokinetics-and-safety-of-revefenacin-in-subjects-with-impaired-r-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/pharmacokinetics-and-safety-of-revefenacin-in-subjects-with-impaired-r-peer-reviewed-article-COPD

Similar Items